RecallRadar

FDA Drug recall D-0958-2017

BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca Pharmaceuticals LP, Wilmington, D…

On 2017-07-19 the FDA classified a Class I recall of BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca Pharmaceuticals LP, Wilmington, D… by Astrazeneca Pharmaceuticals, citing presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addit….

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0958-2017
ClassificationClass I
Statusterminated
Initiated2017-05-25
Published2017-07-19
Last updated2026-09-13 11:51 UTC
CompanyAstrazeneca Pharmaceuticals
DistributionUS

Product

BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850; By: AstraZeneca AB, SE-151 85 Sodertalje, Sweden, NDC 0186-0777-08.

Reason

Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.

Identifiers

ndc0186-0777-08
ndc0186-0777-60
ndc0186-0777-18
ndc0186-0777-39
ndc0186-0777-28
ndc0186-0776-60
ndc0186-0776-94
code_infoLot # JB5047, Exp 10/19

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0958-2017%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.